Vitiligo - Drug Pipeline Landscape, 2023

Vitiligo - Drug Pipeline Landscape, 2023

Vitiligo is a chronic disorder that causes patches of skin to lose pigment or color, when melanocytes are attacked and destroyed, causing the skin to turn a milky-white color. There are two types of vitiligo such as nonsegmental or generalized vitiligo and segmental vitiligo. Nonsegmental or generalized vitiligo happens when the white patches appear symmetrically on both sides of body, such as on both hands or both knees. Segmental vitiligo happens when the white patches are only on one segment or side of body, such as a leg, one side of the face, or arm.

The cause of vitiligo is unknown but researchers believe that vitiligo as an autoimmune disease. It's is not clear exactly what causes these pigment cells to fail or die. Researchers suggest that it may be related to a disorder of the immune system (autoimmune condition), family history (heredity), a trigger event, such as stress, severe sunburn or skin trauma, such as contact with a chemical.

Symptoms of Vitiligo include patchy loss of skin color, premature hair graying, loss of color in the tissues that line the inside of the mouth and nose.

Diagnosis of vitiligo is easy as the white patches are visible on the skin, but doctors use a Wood’s lamp, which shines ultraviolet (UV) light onto the skin to help differentiate from other skin conditions. Doctors may also suggest for other tests can include blood tests to check for other autoimmune diseases, an eye exam to check for uveitis, and a skin biopsy. Doctors can examine the tissue for the missing melanocytes seen in the depigmented skin of a person with vitiligo.

Treatments of Vitiligo can include medicines or medicated skin creams, use of light (phototherapy) to help return color to the skin, depigmentation and dermatologists may consider surgical techniques for long-standing segmental vitiligo.

There are many companies that are active in the development of vitiligo drugs. Some of these companies include AbbVie, Ahammune Biosciences Pvt. Ltd, Arcutis Biotherapeutics, Arrien Pharmaceuticals, Bristol-Myers Squibb etc.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Vitiligo treatment such as Ritecitinib, Afamelanotide, VYN201, and others. Key players involved in the development of therapies to treat Vitiligo are AbbVie Inc, Pfizer, VYNE Therapeutics and others. One drug is under Phase III clinical trials and ten drugs are in Phase II clinical trials and some other drugs are under Phase I, IND/CTA filed, preclinical and discovery stages of development. In Oct 2022, Clinuvel Pharmaceuticals Ltd has enrolled first patient in a new clinical study (CUV104) evaluating the safety and efficacy of afamelanotide.

Report Highlights

Global Insight Service's, Vitiligo - Drug Pipeline Landscape, 2023 report provides an overview of the Vitiligo pipeline drugs. This report covers detailed insights on Vitiligo drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Vitiligo pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.


The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.


The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
To plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.

1. Introduction
1.1 Vitiligo - Pipeline Drugs, 2023 - Coverage
2. Disease Overview - Vitiligo
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management
3. Vitiligo - Pipeline Drugs Development - Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2023
3.3 Products under Development by Companies, 2023
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration
5. Drug Profiles
5.1 Clinical Stage Drugs – Phase III
5.1.1 Ritlecitinib
5.2 Clinical Stage Drugs – Phase II
5.2.1 Afamelanotide
5.2.2 AS012
5.2.3 Cerdulatinib
5.2.4 Crisaborole
5.2.5 EB-06
5.2.6 Ordesekimab
5.2.7 PF-07038124
5.2.8 Povorcitinib
5.2.9 Ritlecitinib
5.2.10 Upadacitinib
5.3 Clinical Stage Drugs – Phase I
5.3.1 EI-001
5.3.2 Rosnilimab
5.3.3 VYN201
5.4 Early-Stage Drugs – IND/CTA Filed
5.4.1 AC-1101
5.5 Early-Stage Drugs – Preclinical
5.5.1 2AP05
5.5.2 AB1001
5.5.3 APIRx
5.5.4 ARN-4079
5.5.5 ARQ-252
5.5.6 AVT-001
5.5.7 FB-102
5.5.8 QY211
5.5.9 TDM-Scar01
5.6 Early-Stage Drugs – Discovery
5.6.1 Immunotherapy
5.6.2 TT-01
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 2A Pharma ApS
9.2 AbbVie Inc
9.3 Ahammune Biosciences Pvt Ltd
9.4 Amgen Inc
9.5 AnaptysBio Inc
9.6 APIRx
9.7 Arcutis Biotherapeutics Inc
9.8 Arrien Pharmaceuticals LLC
9.9 Avotres Inc
9.10 Clinuvel Pharmaceuticals Ltd
9.11 Dermavant Sciences Inc
9.12 Edesa Biotech Inc
9.13 Elixiron Immunotherapeutics Inc
9.14 E-nitiate Biopharmaceuticals (Hangzhou) CoLtd
9.15 Forte Biosciences Inc
9.16 Incyte Corporation
9.17 Pfizer
9.18 Sun Pharmaceutical Industries Ltd
9.19 TechnoDerma Medicines Inc
9.20 Temprian Therapeutics Inc
9.21 TWi Biotechnology Inc
9.22 VYNE Therapeutics Inc
10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
11. Appendix
List of Tables
Table 1. 2 Number of Products under Development by Companies
Table 1. 3 Products under Development by Companies
Table 1. 4 Products by Targets
Table 1. 5 Products by Mechanism of Action
Table 1. 6 Products by Molecule Type
Table 1. 7 Products by Route of Administration
Table 2.1 Clinical Trial Details – Ritlecitinib/Pfizer
Table 2.2 Clinical Trial Details – Afamelanotide/Clinuvel Pharmaceuticals Ltd
Table 2.3 Clinical Trial Details – AS012/Sun Pharmaceutical Industries Ltd
Table 2.4 Clinical Trial Details – Cerdulatinib/Dermavant Sciences Inc
Table 2.5 Clinical Trial Details – Crisaborole/Pfizer
Table 2.6 Clinical Trial Details – Ordesekimab/Amgen Inc
Table 2.7 Clinical Trial Details – PF 07038124/Pfizer
Table 2.8 Clinical Trial Details – Povorcitinib/Incyte Corporation
Table 2.9 Clinical Trial Details – ritlecitinib/Pfizer
Table 2.10 Clinical Trial Details – Upadacitinib/AbbVie Inc
Table 2.11 Clinical Trial Details – EI-001/Elixiron Immunotherapeutics Inc
Table 3. 1 Regulatory Designations
Table 4. 1 Inactive Drugs
Table 4. 2 Discontinued Drugs
List of Figures
Figure 1. 1 Number of Products under Development for Vitiligo, 2023
Figure 1. 2 Products by Top 5 Targets and Stage of Development for Vitiligo, 2023
Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Vitiligo, 2023
Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Vitiligo, 2023
Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Vitiligo, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings